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model was constructed with four health states regarding survival
and irreversible adverse events. Health care costs and effects of
SBRT, proton therapy and carbon-ion therapy were compared
over a ﬁve-year time horizon. Transition probabilities were
derived from single-armed observational studies, as no compara-
tive studies were available. Utilities were collected in a cross-
sectional survey. Probabilistic sensitivity analysis was performed
to reﬂect parameter uncertainty. RESULTS: Preliminary results
showed that the expected total health care costs per patient for
SBRT were €18,366, for protons €24,267 and for carbon-ions
€26,720. The expected quality adjusted life-years (QALYs) were
2.24, 2.40 and 2.45 respectively. This resulted in an incremental
cost-effectiveness ratio (ICER) of €36,651 per QALY for protons
as opposed to SBRT, and an ICER of €44,668 per QALY for
carbon-ions as opposed to protons. For a ceiling ratio of €40,000
protons had the highest probability of being cost-effective (41%),
followed by carbon-ions (35%) and SBRT (24%). For a ceiling
ratio of €80,000 these probabilities were 42%, 52% and 6%
respectively. CONCLUSIONS: These preliminary results indicate
that PT is a potentially cost-effective treatment modality for
inoperable stage I NSCLC. However, caution is warranted, as the
differences are small and surrounded by considerable uncer-
tainty. More analyses will be performed of which the results are
presented at the conference. First, more advanced statistical tech-
niques are applied to synthesize the available evidence. Second,
for operable patients PT is compared to surgery. Third, the
cost-effectiveness of PT is assessed for stage III NSCLC. Finally,
expected value of perfect information analyses are presented to
support research decisions.
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Achieving complete cytogenetic response (CCyR) is associated
with superior progression-free survival in patients with CML [1].
How this endpoint affects cost has not been evaluated. OBJEC-
TIVES: To assess the cost needed to achieve one CCyR with
dasatinib 140 mg vs. imatinib 600 and 800 mg in imatinib-
resistant CP-CML, from the perspective of national health
insurance in the Czech Republic, Hungary and Romania.
METHODS: An economic analysis was conducted using the
number of patients needed to be treated (NNT) to achieve one
CCyR. The incremental cost for achieving CCyR in 15 months
was determined. CCyR rates for dasatinib 140 and imatinib
800 mg were based on a randomized phase 2 trial START-R [2].
Given no published data on imatinib 600 mg, its CCyR rate was
assumed to be the same as for imatinib 800 mg; an assumption in
favor of imatinib. Costs were based on reimbursed drug-prices
from national lists. In Hungary, reimbursed amounts for 600 or
800 mg of imatinib are the same. RESULTS: To achieve one
CCyR, NNT is 6,25 for imatinib and 2,5 for dasatinib. The costs
to achieve one CCyR during 15 months of therapy are CZK9,1
million (€363,172), HUF52.8 million (€218,492) and RON1.2
million (€334,146) lower for dasatinib compared to imatinib
800 mg. The economic advantage of dasatinib remains when
compared to imatinib 600 mg. The incremental costs to achieve
one CCyR between imatininb 600 mg and dasatinib are CZK5.7
million (€228,664), HUF52,8 million (€218,492) and RON0.7
million (€205,316). CONCLUSIONS: In imatinib-resistant
CP-CML patients, therapy with dasatinib provides better efﬁcacy
and lower cost compared to imatinib 600 and 800 mg in Central
and Eastern Europe to achieve one CCyR. The magnitude of the
advantage varies due to different pricing and ﬁnancing systems.
[1] Hughes et al. NEJM 2003;349:1423–32; [2] Kantarjian et al.
Blood 2007;109:5143–50.
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OBJECTIVES: Diabetes affects over 2.3 million people in UK;
approximately 10% have type 1 diabetes (T1DM). The aim of
this study was to evaluate the long-term cost and clinical out-
comes associated with lispro versus regular human insulin (RHI)
in the UK T1DM patients using the previously published and
validated CORE Diabetes Model. METHODS: Several clinical
trials have provided evidence that short-acting insulin analogs,
with improved pharmacokinetic properties, may have beneﬁts in
terms of glycaemic control (HbA1c) and hypoglycemic event
rates compared to mealtime human insulin. For the simulations,
clinical beneﬁts were derived from a recent Cochrane meta-
analysis which found the weighted mean difference in HbA1c to
be -0.1% (95% CI -0.2% to -0.0%) for treatment with lispro
versus RHI. Major hypoglycaemic event rates for lispro and RHI
were 21.8 and 46.1 per 100 patient-years, respectively. Current
prices of insulin lispro (Humalog), regular human insulin
(Humulin R) and basal NPH insulin (Humulin I) were obtained
from http://www.mims.co.uk. Complication costs and patient
management costs (screening and concomitant medications)
were derived from published sources. All costs were accounted in
2007 Pounds Sterling (£) from a National Health Service (NHS)
perspective. Future costs and clinical beneﬁts were discounted at
3.5% annually. RESULTS: Model projections indicated that
lispro was associated with a beneﬁt in quality-adjusted life
expectancy of approximately 0.10 QALYS versus RHI (7.60
versus 7.50 QALYs). Lifetime direct medical costs per patient
were lower with lispro treatment, £70,576 versus £72,529.
Lispro was projected to be dominant (lower cost: more beneﬁt)
compared to RHI. Results were robust to sensitivity analyses
including time horizon, discounting rates and scenarios assum-
ing beneﬁt only on glycaemic control or hypoglycemia rates.
CONCLUSIONS: The study suggests that lispro is likely to
improve quality-adjusted life expectancy and reduce costs in UK
patients with T1DM, due principally to beneﬁts in hypoglycemic
event rates.
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OBJECTIVES: To estimate the impact of overweight or obesity
on treatment costs(TCs) in diabetic patients in the United States.
METHODS: Five-year (2001–2005) pooled Medical Expendi-
ture Panel Survey data, a nationally representative sample of U.S.
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